[6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone | 1159602-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: [6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone
• 英文别名: [6-(5-Methyl-3-pyridin-2-yl-isoxazol-4-ylmethoxy)-pyridin-3-yl]-morpholin-4-yl-methanone；[6-[(5-methyl-3-pyridin-2-yl-1,2-oxazol-4-yl)methoxy]pyridin-3-yl]-morpholin-4-ylmethanone
• CAS: 1159602-81-9
• 化学式: C₂₀H₂₀N₄O₄
• 分子量: 380.403
• InChiKey: VQORXIASXUHNLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-(5-methyl-3-pyridin-2-yl-isoxazol-4-ylmethoxy)-nicotinic acid methyl ester 、 吗啉 以to the title compound (90 mg, 79%) which was obtained as a white solid的产率得到[6-(5-methyl-3-pyridin-2-ylisoxazol-4-ylmethoxy)pyridin-3-yl]morpholin-4-ylmethanone
  参考文献：
  名称：

  ISOXAZOLO-PYRIDINE DERIVATIVES

  摘要：

  本发明涉及式I的异唑嗪-吡啶衍生物，其中X，R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性，可用于治疗认知障碍，如阿尔茨海默病。

  公开号：

  US20130274468A1

文献信息

• ISOXAZOLE-PYRIDINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20090143371A1

  公开（公告）日：2009-06-04

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R 1 to R 6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异恶唑-吡啶衍生物 其中X，R1至R6如本文所述。这些化合物对GABA A α5受体结合位点具有活性，并可用于治疗认知障碍，如阿尔茨海默病。
• Isoxazolo-pyridine derivatives
  申请人：Roche Palo Alto LLC

  公开号：US08877782B2

  公开（公告）日：2014-11-04

  The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.

  本发明涉及式I的异噁唑-吡啶衍生物，其中X，R1至R6如本文所述。该化合物对GABA A α5受体结合位点具有活性，可用于治疗认知障碍，如阿尔茨海默病。
• Use of active pharmaceutical compounds for the treatment of central nervous system conditions
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2457569A1

  公开（公告）日：2012-05-30

  The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions caused by neurodevelopmental defects which result in excessive GABAergic inhibition in the cortex and hippocampus.

  本发明涉及选择性GABA A α5负异位调节剂的药物用途，用于治疗、预防和/或延缓由神经发育缺陷引起的中枢神经系统（CNS）疾病的进展，神经发育缺陷导致大脑皮层和海马中GABA能抑制过度。
• USE OF ACTIVE PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2635277B1

  公开（公告）日：2018-12-19
• USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS
  申请人：Gasser Rodolfo

  公开号：US20120115839A1

  公开（公告）日：2012-05-10

  The present invention relates to the pharmaceutical use of selective GABA A α5 negative allosteric modulators for the treatment, prevention and/or delay of progression of central nervous system (CNS) conditions related to excessive GABAergic inhibition in the brain.